Madrigal Pharmaceuticals, Inc.MDGLNASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank79
3Y CAGR+44.3%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
+44.3%/yr
vs -25.7%/yr prior
Acceleration
+70.0pp
Accelerating
Percentile
P79
Within normal range
vs 3Y Ago
3x
Strong expansion
Streak
1 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2025 | 87.06% |
| 2024 | 302.29% |
| 2023 | 124.70% |
| 2022 | 28.97% |
| 2021 | 70.68% |
| 2020 | -3.46% |
| 2019 | 51.28% |
| 2018 | 95.14% |
| 2017 | -17.42% |
| 2016 | -30.63% |